Premium
Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial
Author(s) -
Leelaphiwat Supatra,
Jongwutiwes Theerayut,
Lertvikool Srithean,
Tabcharoen Chotika,
Sukprasert Matchuporn,
Rattanasiri Sasivimol,
Weerakiet Sawaek
Publication year - 2015
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12543
Subject(s) - desogestrel , cyproterone acetate , hyperandrogenism , medicine , polycystic ovary , cyproterone , endocrinology , antiandrogen , spironolactone , ethinylestradiol , androstenedione , hirsutism , acne , medroxyprogesterone acetate , sex hormone binding globulin , free androgen index , androgen , hormone , population , insulin resistance , aldosterone , environmental health , dermatology , family planning , insulin , research methodology
Aim To compare the effects of ethinyl estradiol ( EE ) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A ) versus EE 35 mcg/cyproterone acetate 2 mg (group B ) on hyperandrogenism and metabolism in PCOS . Methods This was a randomized clinical study. Eighteen women in groups A and B received medications for three cycles. Acne score, androgens and metabolic parameters were assessed before and after treatment. Results One and two women in groups A and B , respectively, were excluded from the study. Both groups had significantly decreased acne score and free androgen index, and increased sex hormone‐binding globulin levels. Cholesterol and high‐density lipoprotein were significantly increased in group B , and androstenedione was significantly decreased in group A . The regular withdrawal bleeding was obtained in both groups. Conclusion Both regimens had quite similar efficacy on hyperandrogenism after three cycles of therapy and without any changes in metabolic parameters.